title: Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.
authors.forename: A
authors.initials: A
authors.lastname: Wick
authors.forename: N
authors.initials: N
authors.lastname: Schäfer
authors.forename: N
authors.initials: N
authors.lastname: Dörner
authors.forename: D
authors.initials: D
authors.lastname: Schemmer
authors.forename: M
authors.initials: M
authors.lastname: Platten
authors.forename: M
authors.initials: M
authors.lastname: Bendszus
authors.forename: W
authors.initials: W
authors.lastname: Wick
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001158:Arteries / Q000187:drug effects / Q000503:physiopathology; D000068258:Bevacizumab; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab